BEIGF:OTCMKTS
BeOne Medicines
$21.95
0.00%
(0.00) 1D
$27.04
arrow_upward
+23.23% (+5.10)todayPre-market
Sarado: Hun 9, 12:49:46 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa BEIGF...
Mkt. cap
43.19B
Avg. na dami
0.00
Dami
130.00K
Mataas nang 52-wk
$24.92
Mababa nang 52-wk
$21.95
Beta
0.84
Mga natitirang share
1.43B
Bilang ng mga empleyado
12K
Mkt. cap
43.19B
Avg. na dami
0.00
Dami
130.00K
Mataas nang 52-wk
$24.92
Mababa nang 52-wk
$21.95
Beta
0.84
Mga natitirang share
1.43B
Bilang ng mga empleyado
12K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketBeat
·
7 oras ang nakalipas
Sanders Morris Harris LLC Makes New Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Simply Wall Street
·
13 oras ang nakalipas
BeOne Medicines (ONC) Stock Trades Above Fair Value Following Its 103% Run
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tungkol sa BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Mga Empleyado12K
ItinatagOkt 28, 2010
Headquarters-
Sektor-
Websitebeonemedicines.com